can you use glp 1 with sglt2 What to know about using non-insulin agents in type diabetes Meta-analysis: SGLT2 inhibitors and GLP-1RAs

More caution is warranted

The semaglutide group experienced a mean body weight reduction of 17.4% compared to 1.8% in the placebo group, along with improvements in multiple cardiometabolic risk parameters.96 Orforglipron, a once-daily oral non-peptide GLP-1RAs, exhibits a distinct mode of interaction with the GLP-1 receptor compared to native GLP-1

Theres no universal best choice among Wegovy, Ozempic, and Saxenda

There's no standard of care for how to de-escalate therapy, and so different physicians have different experiences and practices, adds Biermann

A Risk Reduction Aspirin is effective in reducing CV morbidity and mortality in high-risk patients with previous myocardial infarction (MI) or stroke (secondary prevention) and is strongly recommended